FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W100481344> ?p ?o ?g. }

• W100481344 abstract "Abstract Background Bendamustine is a chemotherapeutic drug with structural similarities to both alkylating agents (nitrogen mustard derivative) and purine analogues (benzimidazole ring). Theoretically, due to its nucleoside-like properties it might be associated with more infections. Data in the literature is lacking regarding the infection-related adverse events of bendamustine-containing regimens. Thus, we aimed to assess this risk. Methods Systematic review and meta-analysis of all randomized controlled trials comparing bendamustine containing regimens (alone or combined with other chemotherapeutic agents and/or rituximab) to any other regimens. Trials evaluating bendamustine for any indication (hematological as well as solid malignancies) were included. A comprehensive search of The Cochrane Library, MEDLINE, conference proceedings and references was conducted until July 2013. Two reviewers appraised the quality of trials and extracted data. Outcomes assessed were: any infections, grade 3-4 infections, fatal infections, grade 3-4 neutropenia and grade 3-4 lymphopenia. For dichotomous data, relative risks (RR) with 95% confidence intervals (CIs) were estimated and pooled. We used fixed effect model to pool data, unless there was significant heterogeneity, in which case we used the random effects model. Results Ten trials conducted between the years 1998 and 2013 and randomizing 2360 patients were included. We included 4 trials of patients with non-Hodgkin lymphoma (Rummel 2013, Rummel 2010, Herold 2006 and the Bright study 2013), 3 trials of CLL (Knauf 2009, Niederle 2013, LeBlond 2013), 1 trial of patients with multiple myeloma (Ponish 2006) and 2 trials of breast carcinoma patients. The bendamustine arm included: bendamustine alone (2 trials), bendamustine-rituximab (BR) (4 trials), bendamustine, vincristine, prednisone (BOP) (1 trial), bendamustine, MTX. 5FU (BMF) (2 trials) and bendamustine, prednisone (BP) (1 trial). The comparator arms in 8 of the trials included other alkylating agents: chlorambucil, R -CHOP, cyclophosphamide, MTX, 5-FU (CMF) and melphalan-prednisone (MP) – each regimen used in 2 trials and COP used in 1 trial. In 2 trials the comparator arm included fludarabine based regimens (alone or with rituximab). There was no statistically significant effect for bendamustine on the rate of any type of infection (RR 1.06 [95% CI 0.83, 1.34], 6 trials, figure). This analysis included only trials of hematological malignancies. There was no increase in the rate of grade 3-4 infections (RR 1.45 [95% CI 0.86, 2.45], 7 trials) or fatal infection (RR 0.69 [95% CI 0.30, 1.58], 3 trials). Data were too scarce to analyze by specific types of infections separately. There was no increase in the rate of grade 3-4 neutropenia in the bendamustine arm (RR 0.9 [95% CI 0.58, 1.42], 6 trials). This was true both when the comparator was alkylating agent containing regimens (RR 0.87 [95% CI 0.52, 1.48], 4 trials) or fludarabine containing regimens (RR 1.02 [95% CI 0.54, 1.91], 2 trials). There was a significant increase in grade 3-4 lymphopenia in the bendamustine arm compared to alkylating agent containing regimens (RR 1.95[95% CI 1.54, 2.47). Conclusions Our systematic review demonstrates no effect of bendamustine on the rate of infections when compared to either alkylating agents or fludarabine, in hematological as well as in solid malignancies, despite an increase in lymphopenia. Thus, bendamustine remains a safe therapeutic option. The main drawback of this meta-analysis is the heterogeneity between malignancies and treatments. Disclosures: No relevant conflicts of interest to declare." @default.
• W100481344 created "2016-06-24" @default.
• W100481344 creator A5037546722 @default.
• W100481344 creator A5049406914 @default.
• W100481344 creator A5058355502 @default.
• W100481344 creator A5086557065 @default.
• W100481344 date "2013-11-15" @default.
• W100481344 modified "2023-09-27" @default.
• W100481344 title "Bendamustine Is Not Associated With An Increase In Infections – Systematic Review and Meta-Analysis Of Randomized Controlled Trials" @default.
• W100481344 doi "https://doi.org/10.1182/blood.v122.21.5125.5125" @default.
• W100481344 hasPublicationYear "2013" @default.
• W100481344 type Work @default.
• W100481344 sameAs 100481344 @default.
• W100481344 citedByCount "3" @default.
• W100481344 countsByYear W1004813442014 @default.
• W100481344 countsByYear W1004813442015 @default.
• W100481344 crossrefType "journal-article" @default.
• W100481344 hasAuthorship W100481344A5037546722 @default.
• W100481344 hasAuthorship W100481344A5049406914 @default.
• W100481344 hasAuthorship W100481344A5058355502 @default.
• W100481344 hasAuthorship W100481344A5086557065 @default.
• W100481344 hasConcept C126322002 @default.
• W100481344 hasConcept C143998085 @default.
• W100481344 hasConcept C168563851 @default.
• W100481344 hasConcept C197934379 @default.
• W100481344 hasConcept C2776694085 @default.
• W100481344 hasConcept C2777063308 @default.
• W100481344 hasConcept C2779338263 @default.
• W100481344 hasConcept C2780653079 @default.
• W100481344 hasConcept C2781442060 @default.
• W100481344 hasConcept C44249647 @default.
• W100481344 hasConcept C535046627 @default.
• W100481344 hasConcept C71924100 @default.
• W100481344 hasConcept C82789193 @default.
• W100481344 hasConcept C95190672 @default.
• W100481344 hasConceptScore W100481344C126322002 @default.
• W100481344 hasConceptScore W100481344C143998085 @default.
• W100481344 hasConceptScore W100481344C168563851 @default.
• W100481344 hasConceptScore W100481344C197934379 @default.
• W100481344 hasConceptScore W100481344C2776694085 @default.
• W100481344 hasConceptScore W100481344C2777063308 @default.
• W100481344 hasConceptScore W100481344C2779338263 @default.
• W100481344 hasConceptScore W100481344C2780653079 @default.
• W100481344 hasConceptScore W100481344C2781442060 @default.
• W100481344 hasConceptScore W100481344C44249647 @default.
• W100481344 hasConceptScore W100481344C535046627 @default.
• W100481344 hasConceptScore W100481344C71924100 @default.
• W100481344 hasConceptScore W100481344C82789193 @default.
• W100481344 hasConceptScore W100481344C95190672 @default.
• W100481344 hasLocation W1004813441 @default.
• W100481344 hasOpenAccess W100481344 @default.
• W100481344 hasPrimaryLocation W1004813441 @default.
• W100481344 hasRelatedWork W1509445786 @default.
• W100481344 hasRelatedWork W1602166777 @default.
• W100481344 hasRelatedWork W1612286138 @default.
• W100481344 hasRelatedWork W1869200070 @default.
• W100481344 hasRelatedWork W1938426499 @default.
• W100481344 hasRelatedWork W2048545362 @default.
• W100481344 hasRelatedWork W2054261652 @default.
• W100481344 hasRelatedWork W2140884673 @default.
• W100481344 hasRelatedWork W2169017280 @default.
• W100481344 hasRelatedWork W2351711767 @default.
• W100481344 hasRelatedWork W2460609230 @default.
• W100481344 hasRelatedWork W2736755180 @default.
• W100481344 hasRelatedWork W2969955035 @default.
• W100481344 hasRelatedWork W2995132330 @default.
• W100481344 hasRelatedWork W3093504781 @default.
• W100481344 hasRelatedWork W3094833760 @default.
• W100481344 hasRelatedWork W3095017440 @default.
• W100481344 hasRelatedWork W3171726889 @default.
• W100481344 hasRelatedWork W3204526619 @default.
• W100481344 hasRelatedWork W892568000 @default.
• W100481344 isParatext "false" @default.
• W100481344 isRetracted "false" @default.
• W100481344 magId "100481344" @default.
• W100481344 workType "article" @default.